InvestorsObserver
×
News Home

Is Oncolytics Biotech, Inc. (ONCY) a Good Buy in the Healthcare Sector?

Monday, April 12, 2021 11:08 AM | InvestorsObserver Analysts

Mentioned in this article

Is Oncolytics Biotech, Inc. (ONCY) a Good Buy in the Healthcare Sector?

A rating of 99 puts Oncolytics Biotech, Inc. (ONCY) near the top of the Healthcare sector according to InvestorsObserver.

Oncolytics Biotech, Inc.'s score of 99 means that it ranks higher than 99% of stocks in the sector. In addition, its overall score of 47 ranks it higher than 47% of all stocks.

Overall Score - 47
ONCY has an Overall Score of 47. Find out what this means to you and get the rest of the rankings on ONCY!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies in the healthcare sector can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the best stocks in that sector.

Not only are these scores easy to understand, but it is easy to compare stocks to each other. You can find the best stock in healthcare or look for the sector that has the highest average score.

The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Oncolytics Biotech, Inc. Stock Today?

Oncolytics Biotech, Inc. (ONCY) stock is trading at $3.57 as of 10:52 AM on Monday, Apr 12, a loss of -$0.44, or -10.97% from the previous closing price of $4.01. The stock has traded between $3.54 and $4.07 so far today. Volume today is 1,518,873 compared to average volume of 1,926,001.

Click Here to get the full Stock Score Report on Oncolytics Biotech, Inc. (ONCY) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App